April 22, 2013 — A monoclonal antibody targeting a protein known as SFPR2 has been shown by researchers at the University of North Carolina to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma.
A team lead by Nancy Klauber-DeMore uses a monoclonal antibody to effectively reduce the rate of tumor growth.